Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.32
NAS:IDXX's Cash to Debt is ranked lower than
81% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NAS:IDXX: 0.32 )
Ranked among companies with meaningful Cash to Debt only.
NAS:IDXX' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 8.45 Max: No Debt
Current: 0.32
Equity to Asset -0.01
NAS:IDXX's Equity to Asset is ranked lower than
91% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. NAS:IDXX: -0.01 )
Ranked among companies with meaningful Equity to Asset only.
NAS:IDXX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.74 Max: 0.87
Current: -0.01
-0.06
0.87
Interest Coverage 9.84
NAS:IDXX's Interest Coverage is ranked lower than
72% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NAS:IDXX: 9.84 )
Ranked among companies with meaningful Interest Coverage only.
NAS:IDXX' s Interest Coverage Range Over the Past 10 Years
Min: 9.84  Med: 58.07 Max: 276.91
Current: 9.84
9.84
276.91
F-Score: 5
Z-Score: 6.24
M-Score: -2.69
WACC vs ROIC
3.37%
28.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.74
NAS:IDXX's Operating margin (%) is ranked higher than
85% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. NAS:IDXX: 18.74 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:IDXX' s Operating margin (%) Range Over the Past 10 Years
Min: 14.76  Med: 18 Max: 20.3
Current: 18.74
14.76
20.3
Net-margin (%) 11.94
NAS:IDXX's Net-margin (%) is ranked higher than
83% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. NAS:IDXX: 11.94 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:IDXX' s Net-margin (%) Range Over the Past 10 Years
Min: 10.19  Med: 12.46 Max: 13.78
Current: 11.94
10.19
13.78
ROA (%) 13.64
NAS:IDXX's ROA (%) is ranked higher than
93% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NAS:IDXX: 13.64 )
Ranked among companies with meaningful ROA (%) only.
NAS:IDXX' s ROA (%) Range Over the Past 10 Years
Min: 13.44  Med: 15.96 Max: 17.84
Current: 13.64
13.44
17.84
ROC (Joel Greenblatt) (%) 60.02
NAS:IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. NAS:IDXX: 60.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:IDXX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 53.83  Med: 62.77 Max: 85.38
Current: 60.02
53.83
85.38
Revenue Growth (3Y)(%) 14.10
NAS:IDXX's Revenue Growth (3Y)(%) is ranked higher than
79% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NAS:IDXX: 14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:IDXX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.4  Med: 11.2 Max: 23.1
Current: 14.1
8.4
23.1
EBITDA Growth (3Y)(%) 12.00
NAS:IDXX's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NAS:IDXX: 12.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:IDXX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.3  Med: 15.1 Max: 96.9
Current: 12
3.3
96.9
EPS Growth (3Y)(%) 9.00
NAS:IDXX's EPS Growth (3Y)(%) is ranked higher than
68% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NAS:IDXX: 9.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:IDXX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.5  Med: 16 Max: 26.1
Current: 9
-0.5
26.1
» NAS:IDXX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

IDXX Guru Trades in Q3 2015

Ray Dalio 7,826 sh (+85.19%)
RS Investment Management 370,574 sh (+12.62%)
Chuck Royce 1,770,922 sh (+9.54%)
Ruane Cunniff 8,167,274 sh (+1.04%)
Mairs and Power 3,998 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones 10,711 sh (-0.18%)
Ron Baron 7,061,667 sh (-1.53%)
Chris Davis 623,573 sh (-15.00%)
George Soros 6,800 sh (-62.17%)
Jim Simons 33,100 sh (-87.01%)
» More
Q4 2015

IDXX Guru Trades in Q4 2015

Jim Simons 127,700 sh (+285.80%)
Mairs and Power 3,998 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Ray Dalio Sold Out
George Soros Sold Out
Ruane Cunniff 8,027,368 sh (-1.71%)
Ron Baron 6,891,469 sh (-2.41%)
Chuck Royce 1,207,722 sh (-31.80%)
Chris Davis 264,392 sh (-57.60%)
» More
Q1 2016

IDXX Guru Trades in Q1 2016

Columbia Wanger 1,049,000 sh (New)
Jim Simons 437,504 sh (+242.60%)
Mairs and Power 3,998 sh (unchged)
Chris Davis Sold Out
Ron Baron 6,603,503 sh (-4.18%)
Ruane Cunniff 7,668,176 sh (-4.47%)
Chuck Royce 882,612 sh (-26.92%)
» More
Q2 2016

IDXX Guru Trades in Q2 2016

Paul Tudor Jones 5,712 sh (New)
Jim Simons 537,404 sh (+22.83%)
Mairs and Power 3,998 sh (unchged)
Ron Baron 6,584,973 sh (-0.28%)
Chuck Royce 863,812 sh (-2.13%)
Columbia Wanger 370,439 sh (-64.69%)
Ruane Cunniff 107,894 sh (-98.59%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:Q, NYSE:DGX, NAS:DXCM, OTCPK:ERFSF, OTCPK:SSMXY, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:LH, NYSE:A, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:PRAH, OTCPK:CZMWY » details
Traded in other countries:IX1.Germany,
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for the veterinary, bioresearch, water, livestock, poultry and dairy markets.

IDEXX Laboratories Inc was incorporated in 1983. The Company develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. It also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its products and services are: Point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assays; Veterinary reference laboratory diagnostic and consulting services; Practice management systems and services and diagnostic imaging systems used by veterinarians; Biological materials testing, laboratory animal diagnostic instruments and services used by the biomedical research community; Diagnostic, health-monitoring and food safety testing products for livestock, poultry and dairy; Products that test water for certain microbiological contaminants; Point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market. The Company operates through three business segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG); water quality products (Water); and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and food, which it refers to as Livestock, Poultry and Dairy (LPD). Its other operating segment combines and presents products for the human point-of-care medical diagnostics market (OPTI Medical) with its pharmaceutical product line and its out-licensing arrangements. CAG provides to veterinarian's diagnostic capabilities and information management solutions that enhance the health and well-being of pets. The breadth and complementary nature of its products and services comprise a competitive advantage that it refers to as the IDEXX Diagnostic Advantage, providing veterinarians with the tools and services to offer veterinary medical care. The CAG Diagnostics provides diagnostic capabilities that meet veterinarians' diverse needs through a variety of modalities, including in-clinic diagnostic solutions and outside reference laboratory services. Regardless of modality utilized, veterinarians are provided with clinically relevant data which is integrated within its information management technologies. The result is a comprehensive view of patient diagnostic information that is easily accessible by both the veterinarian and pet owner. The water segment provides testing solutions for easy, rapid and accurate detection and quantification of various microbiological parameters in water, helping to ensure water safety for billions of people around the world. Its products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as microbial indicators for potential fecal

Ratios

vs
industry
vs
history
P/E(ttm) 51.23
IDXX's P/E(ttm) is ranked lower than
73% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.60 vs. IDXX: 51.23 )
Ranked among companies with meaningful P/E(ttm) only.
IDXX' s P/E(ttm) Range Over the Past 10 Years
Min: 15.18  Med: 30.91 Max: 51.62
Current: 51.23
15.18
51.62
Forward P/E 41.32
IDXX's Forward P/E is ranked lower than
81% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. IDXX: 41.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 51.23
IDXX's PE(NRI) is ranked lower than
73% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.47 vs. IDXX: 51.23 )
Ranked among companies with meaningful PE(NRI) only.
IDXX' s PE(NRI) Range Over the Past 10 Years
Min: 15.02  Med: 30.7 Max: 51.62
Current: 51.23
15.02
51.62
Price/Owner Earnings (ttm) 51.40
IDXX's Price/Owner Earnings (ttm) is ranked lower than
71% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. IDXX: 51.40 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IDXX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.36  Med: 34.28 Max: 73.8
Current: 51.4
21.36
73.8
P/S 6.15
IDXX's P/S is ranked lower than
67% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. IDXX: 6.15 )
Ranked among companies with meaningful P/S only.
IDXX' s P/S Range Over the Past 10 Years
Min: 1.75  Med: 3.99 Max: 6.21
Current: 6.15
1.75
6.21
PFCF 49.42
IDXX's PFCF is ranked lower than
79% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. IDXX: 49.42 )
Ranked among companies with meaningful PFCF only.
IDXX' s PFCF Range Over the Past 10 Years
Min: 13.03  Med: 34.04 Max: 93.42
Current: 49.42
13.03
93.42
POCF 36.60
IDXX's POCF is ranked lower than
85% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. IDXX: 36.60 )
Ranked among companies with meaningful POCF only.
IDXX' s POCF Range Over the Past 10 Years
Min: 11.44  Med: 24.13 Max: 44.83
Current: 36.6
11.44
44.83
EV-to-EBIT 34.13
IDXX's EV-to-EBIT is ranked lower than
72% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. IDXX: 34.13 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.5  Med: 21.1 Max: 34.8
Current: 34.13
10.5
34.8
EV-to-EBITDA 27.74
IDXX's EV-to-EBITDA is ranked lower than
73% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. IDXX: 27.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDXX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 17.2 Max: 28.3
Current: 27.74
8.3
28.3
PEG 4.17
IDXX's PEG is ranked lower than
73% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 4.17 )
Ranked among companies with meaningful PEG only.
IDXX' s PEG Range Over the Past 10 Years
Min: 0.77  Med: 2.11 Max: 4.56
Current: 4.17
0.77
4.56
Shiller P/E 76.32
IDXX's Shiller P/E is ranked lower than
83% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.43 vs. IDXX: 76.32 )
Ranked among companies with meaningful Shiller P/E only.
IDXX' s Shiller P/E Range Over the Past 10 Years
Min: 26.11  Med: 50.58 Max: 77.76
Current: 76.32
26.11
77.76
Current Ratio 1.00
IDXX's Current Ratio is ranked lower than
87% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. IDXX: 1.00 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.46 Max: 6
Current: 1
0.92
6
Quick Ratio 0.78
IDXX's Quick Ratio is ranked lower than
85% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. IDXX: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.68 Max: 5.14
Current: 0.78
0.71
5.14
Days Inventory 88.85
IDXX's Days Inventory is ranked higher than
50% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. IDXX: 88.85 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s Days Inventory Range Over the Past 10 Years
Min: 77.45  Med: 82.31 Max: 89.55
Current: 88.85
77.45
89.55
Days Sales Outstanding 45.83
IDXX's Days Sales Outstanding is ranked higher than
71% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. IDXX: 45.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.43  Med: 40.46 Max: 45.83
Current: 45.83
37.43
45.83
Days Payable 24.05
IDXX's Days Payable is ranked lower than
86% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. IDXX: 24.05 )
Ranked among companies with meaningful Days Payable only.
IDXX' s Days Payable Range Over the Past 10 Years
Min: 13.82  Med: 22.5 Max: 27
Current: 24.05
13.82
27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 6.20
IDXX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. IDXX: 6.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IDXX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.4  Med: 2.6 Max: 6.2
Current: 6.2
-1.4
6.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 4.23
IDXX's Price/Projected FCF is ranked lower than
74% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. IDXX: 4.23 )
Ranked among companies with meaningful Price/Projected FCF only.
IDXX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 2.4 Max: 4.23
Current: 4.23
1.14
4.23
Price/DCF (Earnings Based) 2.75
IDXX's Price/DCF (Earnings Based) is ranked lower than
71% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. IDXX: 2.75 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.54
IDXX's Price/Median PS Value is ranked lower than
80% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. IDXX: 1.54 )
Ranked among companies with meaningful Price/Median PS Value only.
IDXX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 0.86 Max: 1.82
Current: 1.54
0.45
1.82
Price/Peter Lynch Fair Value 4.52
IDXX's Price/Peter Lynch Fair Value is ranked lower than
83% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.27 vs. IDXX: 4.52 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
IDXX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.88  Med: 1.8 Max: 4.52
Current: 4.52
0.88
4.52
Earnings Yield (Greenblatt) (%) 2.94
IDXX's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. IDXX: 2.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDXX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 4.7 Max: 9.5
Current: 2.94
2.9
9.5
Forward Rate of Return (Yacktman) (%) 12.79
IDXX's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. IDXX: 12.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IDXX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.7  Med: 16.8 Max: 22.4
Current: 12.79
12.7
22.4

More Statistics

Revenue (TTM) (Mil) $1,690
EPS (TTM) $ 2.21
Beta0.25
Short Percentage of Float4.23%
52-Week Range $63.48 - 115.06
Shares Outstanding (Mil)89.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,770 1,921 2,090
EPS ($) 2.30 2.67 3.15
EPS w/o NRI ($) 2.30 2.67 3.15
EPS Growth Rate
(3Y to 5Y Estimate)
-0.60%
Dividends Per Share ($)
» More Articles for NAS:IDXX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on IDEXX Laboratories Aug 17 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Jul 25 2016 
Baron Asset Fund 2nd Quarter Letter Jul 25 2016 
Ruane Cunniff Comments on Idexx Laboratories Jul 13 2016 
Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter Jul 13 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Apr 26 2016 
Baron Asset Fund 1st Quarter Commentary Apr 26 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Jan 14 2016 
Baron Funds Comments on IDEXX Laboratories Nov 04 2015 
Ron Baron's Largest Purchases During Second Quarter Sep 28 2015 

More From Other Websites
Accuray (ARAY) Grapples with Multiple Issues: Dump Now? Sep 27 2016
5 Big Stocks to Buy Following Friday's Selloff Sep 12 2016
Varian (VAR) Acquires Radiotherapy Business of Candela Sep 09 2016
IDEXX Laboratories to Present at Raymond James North American Equities Conference Sep 06 2016
Why IDEXX Laboratories (IDXX) is Poised to Beat Earnings Estimates (Again) Aug 31 2016
Varian Medical Hits 52 week High, Oncology Prospects Bright Aug 30 2016
Animal spirits: consumers' devotion lifts pet-care stocks Aug 24 2016
Animal spirits: consumers' devotion lifts pet-care stocks Aug 24 2016
5 Medical Device Stocks to Buy on Q2 Earnings Aug 23 2016
Baron Funds Comments on IDEXX Laboratories Aug 17 2016
IDEXX Investor Day Aug 17 2016
IDEXX Investor Day Aug 17 2016
Canaccord Fireside Chat Takeaways For Abaxis, Heska Aug 16 2016
IDEXX LABORATORIES INC /DE Financials Aug 09 2016
IDEXX Laboratories to Host 2016 Investor Day Aug 08 2016
Pets Are Big Business Now and These Stocks Are Behind the Trend Aug 08 2016
Pets Are Family Now and These Stocks Are Best in Show Aug 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)